Andres Juan reported grant involving 7,898 derivative units of Moderna, Inc. at $0.00 for $0 on Nov 5, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Operating Officer
Chief Operating Officer
Filed Nov 9, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
7,898Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
7,898Direct
Trade date
Nov 5, 2026Grant
Filed
Nov 9, 2026, 4:38 PM ET4-day reporting delay
Accession
0001682852-26-000199Code A · Transaction 396079
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Grant16,955$0.00$0Trade 396080
2 transaction rows in this filing. Joint filers share the same rows.

MRNA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MRNA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −30%1w ago −17%1d ago −3.9%
Returns since7d30d90d180d1y

Footnotes in full

F1: 25% of this option will vest and become exercisable on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award will vest on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.